P17.47 COMPREHENSIVE PROTEOMIC PROFILING OF BEVACIZUMAB-RESISTANT GLIOBLASTOMA MULTIFORME

Drugs that impair tumour angiogenesis, i.e. therapeutic antibody anti-vascular endothelial growth factor, bevacizumab (BEV), are becoming standard therapy for recurrent GBM, despite having no impact on overall survival times. Resistance to BEV is fatal, and mechanisms are largely unexplored. With ac...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Kaufman, K.L., Ly, L., McKay, M., Mallawaaratchy, D.M., Mactier, S., Crossett, B., Molloy, M., Buckland, M.E., McDonald, K.L., Christopherson, R.I.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2014
Schlagworte:
Poster Presentations
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4185745/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou174.376
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge